^
    almost2years
    Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov)
    P1/2, N=11, Terminated, LaNova Medicines Development Co., Ltd. | N=265 --> 11 | Trial completion date: Jun 2025 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Feb 2023; company adjusted strategy
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LM-102
    2years
    Study of LM-102 in Subjects in Advanced Tumors (clinicaltrials.gov)
    P1, N=9, Terminated, LaNova Medicines Limited | N=30 --> 9 | Trial completion date: Mar 2023 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: Mar 2023 --> May 2022; Business strategy changed
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LM-102
    3years
    Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov)
    P1/2, N=265, Recruiting, LaNova Medicines Development Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LM-102
    over3years
    Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov)
    P1/2, N=265, Not yet recruiting, LaNova Medicines Development Co., Ltd.
    Clinical • New P1/2 trial • Combination therapy
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LM-102
    over3years
    Study of LM-102 in Subjects in Advanced Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, LaNova Medicines Limited | Initiation date: Dec 2020 --> Jun 2021
    Clinical • Trial initiation date
    |
    CLDN18 (Claudin 18)
    |
    LM-102